SurinameTuberculosis profile
Population  2017 <1 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.015 (0.013–0.018) 2.7 (2.3–3.2)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 1 (0.72–1.3)
Incidence  (includes HIV+TB) 0.16 (0.12–0.2) 29 (22–36)
Incidence (HIV+TB only) 0.027 (0.017–0.038) 4.7 (3.1–6.8)
Incidence (MDR/RR-TB)** <0.01 (<0.01–0.02) 1.6 (0.41–3.5)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females <0.01 (<0.01–0.013) 0.049 (0.031–0.068) 0.059 (0.039–0.079)
Males 0.01 (<0.01–0.014) 0.093 (0.058–0.13) 0.1 (0.068–0.14)
Total 0.019 (0.014–0.024) 0.14 (0.1–0.18) 0.16 (0.12–0.2)
TB case notifications, 2017  
Total cases notified 137
Total new and relapse 129
          - % tested with rapid diagnostics at time of diagnosis 89%
          - % with known HIV status 92%
          - % pulmonary 88%
          - % bacteriologically confirmed among pulmonary 80%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.13 (0.1–0.17)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 23 18%
          - on antiretroviral therapy 16 70%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  7
(0–13)
Estimated % of TB cases with MDR/RR-TB 6.1% (1.7–15) 0% (0–41)  
% notified tested for rifampicin resistance 58% 75% 82
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 8, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 68% 114
Previously treated cases, excluding relapse, registered in 2016 50% 2
HIV-positive TB cases registered in 2016 58% 26
MDR/RR-TB cases started on second-line treatment in 2015   0
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2018  
National TB budget (US$ millions) 1.6
Funding source: 25% domestic, 26% international, 50% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-09-19 Data: www.who.int/tb/data